NASDAQ:EDIT Editas Medicine (EDIT) Stock Price, News & Analysis $5.65 +0.08 (+1.44%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.51▼$5.8550-Day Range$4.54▼$6.0452-Week Range$4.45▼$11.69Volume1.02 million shsAverage Volume1.94 million shsMarket Capitalization$464.66 millionP/E RatioN/ADividend YieldN/APrice Target$12.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Editas Medicine alerts: Email Address Editas Medicine MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside128.3% Upside$12.90 Price TargetShort InterestHealthy19.20% of Shares Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.88Based on 9 Articles This WeekInsider TradingAcquiring Shares$253,800 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.70) to ($2.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.77 out of 5 starsMedical Sector48th out of 936 stocksBiological Products, Except Diagnostic Industry6th out of 154 stocks 4.2 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 4 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageEditas Medicine has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Editas Medicine's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted19.20% of the outstanding shares of Editas Medicine have been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Editas Medicine has recently decreased by 5.68%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEditas Medicine has received a 71.58% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Editas Medicine is -0.78. Previous Next 3.3 News and Social Media Coverage News SentimentEditas Medicine has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Editas Medicine this week, compared to 3 articles on an average week.Search Interest21 people have searched for EDIT on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -24% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have bought 50.38% more of their company's stock than they have sold. Specifically, they have bought $253,800.00 in company stock and sold $168,768.00 in company stock.Percentage Held by InsidersOnly 1.90% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Editas Medicine's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to grow in the coming year, from ($2.70) to ($2.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Editas Medicine's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Editas Medicine Stock (NASDAQ:EDIT)Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Read More EDIT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EDIT Stock News HeadlinesJuly 23 at 4:25 AM | insidertrades.comInsider Selling: Editas Medicine, Inc. (NASDAQ:EDIT) EVP Sells 6,619 Shares of StockJuly 23 at 5:04 AM | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) EVP Baisong Mei Sells 6,619 Shares of StockJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 19, 2024 | finance.yahoo.comEditas Medicine Inc (8EM.MU)July 17, 2024 | investorplace.com3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July EditionJune 26, 2024 | investorplace.comRags to Riches: 3 Gene Editing Stocks That Could Make Early Investors RichJune 14, 2024 | globenewswire.comEditas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual CongressJune 14, 2024 | globenewswire.comEditas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual CongressJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.May 28, 2024 | finance.yahoo.comAzzur Cleanrooms on Demand™ Grand Opening in Devens, MA Brings Together Local, State and Life Sciences LeadersMay 23, 2024 | msn.comUnique gene editing drug could treat genetic blindness, but how it compares to existing therapiesMay 15, 2024 | seekingalpha.comEditas Medicine: Promising Milestone Achieved But Be PatientMay 14, 2024 | finance.yahoo.comDirector Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (EDIT)May 14, 2024 | globenewswire.comEditas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in JuneMay 12, 2024 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth PotentialMay 10, 2024 | markets.businessinsider.comEditas Medicine Hold Rating: Balancing Pipeline Potential with Financial and Legal PrudenceMay 10, 2024 | globenewswire.comEditas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual MeetingSee More Headlines Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EDIT CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees230Year FoundedN/APrice Target and Rating Average Stock Price Target$12.90 High Stock Price Target$20.00 Low Stock Price Target$7.00 Potential Upside/Downside+128.3%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-153,220,000.00 Net Margins-239.36% Pretax Margin-239.36% Return on Equity-47.34% Return on Assets-33.46% Debt Debt-to-Equity RatioN/A Current Ratio4.60 Quick Ratio4.60 Sales & Book Value Annual Sales$78.12 million Price / Sales5.95 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book1.32Miscellaneous Outstanding Shares82,240,000Free Float80,675,000Market Cap$464.66 million OptionableOptionable Beta2.01 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Gilmore O'Neill M.D. (Age 60)President, CEO & Director Comp: $1.04MMr. Erick J. Lucera C.F.A. (Age 56)CPA, CFO & Executive VP Comp: $911.46kDr. Linda C. Burkly Ph.D. (Age 67)Executive VP & Chief Scientific Officer Comp: $522.44kDr. Baisong Mei M.D. (Age 60)Ph.D., Executive VP & Chief Medical Officer Comp: $654.9kDr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberDr. George McDonald Church Ph.D. (Age 70)Co-Founder & Scientific Advisory Board Member More ExecutivesKey CompetitorsREGENXBIONASDAQ:RGNXAdverum BiotechnologiesNASDAQ:ADVMbluebird bioNASDAQ:BLUECellectisNASDAQ:CLLSSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 11,332 shares on 7/26/2024Ownership: 0.360%Allspring Global Investments Holdings LLCBought 20,396 shares on 7/26/2024Ownership: 0.025%Linda BurklySold 11,886 sharesTotal: $64,422.12 ($5.42/share)Aries Wealth ManagementBought 13,850 shares on 7/25/2024Ownership: 0.017%Hennion & Walsh Asset Management Inc.Bought 168,371 shares on 7/20/2024Ownership: 0.205%View All Insider TransactionsView All Institutional Transactions EDIT Stock Analysis - Frequently Asked Questions How have EDIT shares performed this year? Editas Medicine's stock was trading at $10.13 at the beginning of the year. Since then, EDIT shares have decreased by 44.2% and is now trading at $5.65. View the best growth stocks for 2024 here. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.13. The business's quarterly revenue was down 88.9% compared to the same quarter last year. When did Editas Medicine IPO? Editas Medicine (EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. Who are Editas Medicine's major shareholders? Editas Medicine's top institutional investors include Raymond James & Associates (0.64%), Bank of New York Mellon Corp (0.36%), Hennion & Walsh Asset Management Inc. (0.20%) and Assenagon Asset Management S.A. (0.03%). Insiders that own company stock include Gilmore Neil O'neill, Baisong Mei, Michelle Robertson, Bruce Eaton, Linda Burkly, Jessica Hopfield, Mark S Shearman, Lisa Anne Michaels and James C Mullen. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD) and Alibaba Group (BABA). This page (NASDAQ:EDIT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
